BR0114978A - Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares - Google Patents

Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares

Info

Publication number
BR0114978A
BR0114978A BR0114978-4A BR0114978A BR0114978A BR 0114978 A BR0114978 A BR 0114978A BR 0114978 A BR0114978 A BR 0114978A BR 0114978 A BR0114978 A BR 0114978A
Authority
BR
Brazil
Prior art keywords
metabolic
compositions
useful
methods
diseases
Prior art date
Application number
BR0114978-4A
Other languages
English (en)
Inventor
Michele F Browner
Marc Labelle
David L Ckark
Xiaolin Hao
Timothy D Cushing
Ronald C Hawley
Xiao He
Juan C Jaen
Sharada S Labadie
Marie-Louise Smith
Francisco X Talamas
Nigel P C Walker
Original Assignee
Tularik Inc
Hofmann La Roche Ag F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tularik Inc, Hofmann La Roche Ag F filed Critical Tularik Inc
Publication of BR0114978A publication Critical patent/BR0114978A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

"COMPOSIçõES E MéTODOS QUE SãO úTEIS NO TRATAMENTO DE CONDIçõES OU DOENçAS INFLAMATóRIAS, METABóLICAS, E PROLIFERATIVAS CELULARES". São aqui fornecidos compostos, composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares. Em particular, a invenção fornece compostos que modulam a expressão e/ou função de proteínas envolvidas na inflamação, metabolismo, e proliferação celular. Os compostos em questão contêm anéis carbocíclicos ou heterocíclicos fundidos.
BR0114978-4A 2000-10-26 2001-10-23 Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares BR0114978A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24358100P 2000-10-26 2000-10-26
PCT/US2001/051403 WO2002041843A2 (en) 2000-10-26 2001-10-23 Antiinflammation agents

Publications (1)

Publication Number Publication Date
BR0114978A true BR0114978A (pt) 2004-04-20

Family

ID=22919310

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114978-4A BR0114978A (pt) 2000-10-26 2001-10-23 Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares

Country Status (20)

Country Link
US (3) US6846834B2 (pt)
EP (1) EP1333834B1 (pt)
JP (1) JP4285602B2 (pt)
KR (1) KR20030064773A (pt)
CN (1) CN1503673A (pt)
AR (1) AR035499A1 (pt)
AT (1) ATE392898T1 (pt)
AU (2) AU3980602A (pt)
BR (1) BR0114978A (pt)
CA (1) CA2427284A1 (pt)
DE (1) DE60133758T2 (pt)
EA (1) EA200300508A1 (pt)
ES (1) ES2305125T3 (pt)
IL (1) IL155519A0 (pt)
MX (1) MXPA03003599A (pt)
NO (1) NO20031869L (pt)
NZ (1) NZ525474A (pt)
PL (1) PL366114A1 (pt)
WO (1) WO2002041843A2 (pt)
ZA (1) ZA200303203B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
IL155519A0 (en) 2000-10-26 2003-11-23 Tularik Inc Antiinflammation agents
JP2005511608A (ja) * 2001-11-07 2005-04-28 エフ．ホフマン−ラ　ロシュ　アーゲー アミノピリミジン類及び−ピリジン類
WO2003048152A2 (en) 2001-12-05 2003-06-12 Tularik Inc. Inflammation modulators
BR0311605A (pt) 2002-06-06 2005-02-22 Boehringer Ingelheim Pharma Compostos de amida de ácido 3-aminotieno[2,3-b]piridina-2-carboxìlico substituìdo e processos para preparação e seus usos
US7199119B2 (en) 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
US7521062B2 (en) 2002-12-27 2009-04-21 Novartis Vaccines & Diagnostics, Inc. Thiosemicarbazones as anti-virals and immunopotentiators
US7329764B2 (en) 2003-07-31 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Substitute benzothiophene compounds
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
EP1896072A4 (en) 2005-06-24 2013-01-09 Univ Duke SYSTEM FOR DIRECT HEALTH MANAGEMENT BASED ON HEAT-CONTROLLED BIOPOLYMERS
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
NZ563687A (en) 2005-06-30 2011-07-29 Smithkline Beecham Corp 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]-1H-indole-7-carboxamide for inhibiting IKK2 (aka IKKbeta)
WO2007062318A2 (en) * 2005-11-18 2007-05-31 Smithkline Beecham Corporation Chemical compounds
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
CA2653654A1 (en) 2006-06-06 2007-12-21 Boehringer Ingelheim International Gmbh Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
DE102007012794B3 (de) * 2007-03-16 2008-06-19 Novaled Ag Pyrido[3,2-h]chinazoline und/oder deren 5,6-Dihydroderivate, deren Herstellungsverfahren und diese enthaltendes dotiertes organisches Halbleitermaterial
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
US20100179143A1 (en) * 2007-05-29 2010-07-15 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
KR20190026056A (ko) 2008-04-21 2019-03-12 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US8299055B2 (en) * 2008-10-02 2012-10-30 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and the use thereof
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
CA2903081A1 (en) 2013-03-14 2014-09-25 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
EA201790502A1 (ru) 2014-09-16 2017-10-31 Селджен Квонтисел Рисёрч, Инк. Ингибиторы гистоновых диметилаз
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US11192859B2 (en) * 2016-04-18 2021-12-07 New York University Quinoline compounds as modulators of RAGE activity and uses thereof
CN109689027A (zh) 2016-06-29 2019-04-26 奥德纳米有限公司 甘油三酯耳用制剂及其用途
WO2020176349A1 (en) * 2019-02-25 2020-09-03 The Regents Of The University Of California Nnythiosemicarbazone compounds and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317987D0 (en) * 1993-08-26 1993-10-13 Glaxo Group Ltd Chemical compounds
NZ500590A (en) * 1997-04-22 2001-11-30 Cocensys Inc Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
US6207679B1 (en) 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US5843721A (en) * 1997-07-03 1998-12-01 Tularik Inc. Nucleic acids encoding human NIK protein
US6258822B1 (en) 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
MXPA01012283A (es) 1999-06-23 2002-07-30 Aventis Pharma Gmbh Bencimidazoles sustituidos.
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
AU1182702A (en) 2000-10-03 2002-04-15 Bristol Myers Squibb Co Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
JP2004523476A (ja) 2000-10-12 2004-08-05 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
AU2002211662A1 (en) 2000-10-12 2002-04-22 Smith Kline Beecham Corporation Nf-kappab inhibitors
IL155519A0 (en) 2000-10-26 2003-11-23 Tularik Inc Antiinflammation agents
JP2002193938A (ja) 2000-12-01 2002-07-10 Bayer Ag ４−アリールピリジン誘導体
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
MXPA03006817A (es) 2001-02-01 2003-11-13 Bristol Myers Squibb Co Metodo de tratamiento de enfermedades inflamatorias e inmunes usando inhibidores de la ikb cinasa (ikk).
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases

Also Published As

Publication number Publication date
NO20031869D0 (no) 2003-04-25
CA2427284A1 (en) 2002-05-30
US20050043330A1 (en) 2005-02-24
AU3980602A (en) 2002-06-03
US20070135464A1 (en) 2007-06-14
EA200300508A1 (ru) 2004-06-24
ES2305125T3 (es) 2008-11-01
AU2002239806B2 (en) 2007-01-18
PL366114A1 (en) 2005-01-24
NO20031869L (no) 2003-06-26
AU2002239806B8 (en) 2002-06-03
JP4285602B2 (ja) 2009-06-24
EP1333834B1 (en) 2008-04-23
EP1333834A2 (en) 2003-08-13
EP1333834A4 (en) 2007-01-17
US20020161004A1 (en) 2002-10-31
CN1503673A (zh) 2004-06-09
NZ525474A (en) 2005-10-28
JP2004516252A (ja) 2004-06-03
DE60133758T2 (de) 2009-07-02
ATE392898T1 (de) 2008-05-15
IL155519A0 (en) 2003-11-23
AR035499A1 (es) 2004-06-02
WO2002041843A2 (en) 2002-05-30
US7186841B2 (en) 2007-03-06
ZA200303203B (en) 2004-04-26
KR20030064773A (ko) 2003-08-02
WO2002041843A3 (en) 2003-02-06
US6846834B2 (en) 2005-01-25
MXPA03003599A (es) 2003-08-01
DE60133758D1 (de) 2008-06-05

Similar Documents

Publication Publication Date Title
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
CY1119263T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων
TR200001312T2 (tr) Benzotiyazol protein tirozin kinaz önleyicileri.
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
NO20061736L (no) Krystallform av epotilon B
ATE200677T1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
TR200102817T2 (tr) Antiinflamatuar ajanlar olarak faydalı bileşikler
EA199800667A1 (ru) Новые фенантридины
ATE511840T1 (de) Imidazolderivate als entzündungshemmende mittel
CY1105144T1 (el) Χρηση μιας ουσιας που συνδεεται στον πepιφepειακο υποδοχεα των βενζοδιαζεπινων στη θepαπεια του δepματικου στρες
TR200002218T2 (tr) 2-(Pürin-9-il)-Tetrahidrofüran -3,4-Diol türevleri
BR0206985A (pt) Anticorpos modificados e métodos de uso
ATE413386T1 (de) Ppar-gamma modulatoren
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BR0316502A (pt) Compostos quìmicos
ATE231872T1 (de) Thiazolopyrimidinderivate
DK0842934T3 (da) 5-HT1F agonister
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
DE69630955T2 (de) Immortalisierung bzw. desimmortalisierung von zellen
DK0489877T3 (da) Antiatherosklerotiske og antithrombotiske 2-amino-6-phenyl-4H-pyran-4-oner
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A , 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009.